Pihlajamaa P, Sahu B, Lyly L, Aittomki V, Hautaniemi S, Jnne OA
Method-specific prompts and any required references appear inside the checkout flow
This was primarily through the attenuation of lipid peroxidation and enhancements in intracellular response antioxidants, particularly glutathione
Claytons research contributions to PT-141 development include: Principal investigator for pivotal Phase 2 dose-finding trial establishing optimal 1.75 mg dose Lead investigator for RECONNECT Phase 3 trials supporting FDA approval Development of responder analysis methodology for patient-reported outcomes in sexual dysfunction Neurobehavioral research elucidating central mechanisms of sexual desire Extensive publication record on bremelanotide efficacy, safety, and clinical applications Her work has established PT-141 as the second FDA-approved pharmacological treatment for HSDD and the first melanocortin-based therapy for sexual dysfunction, representing a significant advance in womens sexual health treatment options
At the end of treatment, a significantly higher proportion of patients achieved a CAP 302 dB/m (equivalent to mild or absent steatosis, S1): 50% with 1200 mg (95% CI: 36-64
Patients complete a telehealth consultation, receive a prescription if appropriate, and their medication ships directly to their home
